UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 24, 2004
AVANT IMMUNOTHERAPEUTICS, INC.
(Exact name of registrant as specified in charter)
Delaware 0-15006 13-3191702
(State or other jurisdiction (Commission file number) (IRS employer
of incorporation) identification no.)
119 Fourth Avenue
Needham, Massachusetts 02494
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code:
(781) 433-0771
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
99.1 The Company's Press Release dated February 24, 2004.
ITEM 9. REGULATION FD DISCLOSURE.
The following information is furnished under Item 12
of Form 8-K "Results of Operations and Financial
Condition". This information is being furnished and
shall not be deemed "filed" for the purposes of
Section 18 of the Securities Exchange Act of 1934 or
otherwise subject to the liabilities of that Section.
The information in this Current Report on Form 8-K
shall not be incorporated by reference into any
registration statement or other document pursuant to
the Securities Act of 1933 as amended.
On February 24, 2004, the Company issued a press
release which is attached to this Form 8-K as Exhibit
99.1 and incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
AVANT IMMUNOTHERAPEUTICS, INC.
Date: February 24, 2004 By: /s/ Avery W. Catlin
---------------------------------------------
Avery W. Catlin
Senior Vice President and
Chief Financial Officer
EXHIBIT INDEX
Exhibit
Number Description
------ -----------
99.1 The Company's Press Release dated February 24, 2004